Plain-English translation of NCT05956821 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether two medications — cetuximab and bevacizumab — can help treat aggressive brain tumors in young people when the cancer has come back or stopped responding to earlier treatments. The medications are delivered directly into the blood vessels that feed the tumor, rather than given by mouth or IV. The study will give these infusions once a month for up to about a year and carefully watch whether the treatment is safe and whether it helps shrink the tumor.
Many young people with these aggressive brain tumors have few good options once their cancer returns or stops responding to standard chemotherapy. Researchers believe that delivering the medication directly to the tumor through blood vessels might work better and cause fewer side effects than traditional treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would come to the hospital or clinic approximately once a month to receive the two medications delivered directly into an artery that feeds your brain tumor — a procedure called super-selective intraarterial infusion. This treatment would continue for up to about one year. Between visits, you would have blood tests and imaging scans to check how you are doing and whether the tumor is responding. The research team will carefully monitor you for any side effects and watch how your tumor changes over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States